Adding bevacizumab to standard chemotherapy improves overall survival for women with ovarian cancer

the ONA take:

Preliminary findings from the Gynecologic Oncology Group’s (GOG) GOG 213 study show an improvement in overall survival for women with ovarian cancer when bevacizumab is added to standard chemotherapy. The researchers report overall survival was a median 5 months longer for women who received chemotherapy plus bevacizumab than for women who received chemotherapy alone. These findings were presented at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer.

Median overall survival for women in the chemotherapy plus bevacizumab group was 42.2 months, compared with 37.3 months in the group who received chemotherapy alone. The additional drug improved progression-free survival by nearly 3.5 months (13.8 months for chemotherapy plus bevacizumab vs 10.4 months for chemotherapy alone). The ongoing study will assess quality of life in the women who also received bevacizumab and the role of secondary surgery before chemotherapy.

Adding bevacizumab to standard chemotherapy improves overall survival for women with ovarian cancer
Preliminary findings from the Gynecologic Oncology Group’s (GOG) GOG 213 study show an improvement in overall survival for women with ovarian cancer when bevacizumab is added to standard chemotherapy.
In a study presented at a meeting of women's cancer specialists, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs